Tier 2 — strong

Ingestion of quercetin inhibits platelet aggregation and essential components of the collagen-stimulated platelet activation pathway in humans

G P Hubbard, S Wolffram, J A Lovegrove, J M Gibbins
Journal of thrombosis and haemostasis : JTH 2004 2(12):2138

Bibliography

PubMed
PMID 15613018
DOI
10.1111/j.1538-7836.2004.01067.x
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignPilot human supplementation study with ex vivo platelet assays
ModelHuman intervention research
SampleHuman volunteers; sample size not stated in the indexed abstract
InterventionQuercetin-4-glucoside 150 mg or 300 mg
DurationSingle dose; platelet assays at 30 and 120 minutes
EndpointsPlatelet or coagulation measurements; Protein activity, binding or signaling

What the study showed, in plain terms

Published in 2004, this source examined safety, interactions and special populations. Design: Pilot human supplementation study with ex vivo platelet assays. Sample/model: Human volunteers; sample size not stated in the indexed abstract. The exposure or intervention was Quercetin-4-glucoside 150 mg or 300 mg. Follow-up or treatment period: Single dose; platelet assays at 30 and 120 minutes.

Platelet aggregation and selected collagen-signaling responses were reduced after ingestion.

Laboratory platelet responses do not establish prevention of thrombosis, a quantified bleeding risk, or equivalence to antiplatelet medication.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin Side Effects and Safety: A Practical Guide. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Platelet aggregation and selected collagen-signaling responses were reduced after ingestion.
  • The recorded outcome domains were Platelet or coagulation measurements; Protein activity, binding or signaling.
  • The result applies to the tested exposure: Quercetin-4-glucoside 150 mg or 300 mg; Single dose; platelet assays at 30 and 120 minutes.

What this study can and cannot tell us

  • Laboratory platelet responses do not establish prevention of thrombosis, a quantified bleeding risk, or equivalence to antiplatelet medication.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Phase 1 study of quercetin, a natural antioxidant for children and young adults with Fanconi anemia
Parinda A Mehta et al. · Blood advances · 2025
Tier 2
Randomised clinical trial to determine the safety of quercetin supplementation in patients with chronic obstructive pulmonary disease
Meilan K Han et al. · BMJ open respiratory research · 2020
Tier 2
Interaction study between antiplatelet agents, anticoagulants, diabetic therapy and a novel delivery form of quercetin
Antonella Riva et al. · Minerva cardioangiologica · 2019

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology